A phase III trial of TPI-287 in glioblastoma multiforme
Latest Information Update: 23 Dec 2024
Price :
$35 *
At a glance
- Drugs TPI 287 (Primary)
- Indications Glioblastoma
- Focus Registrational; Therapeutic Use
- Sponsors Cortice Bioscience
- 18 Nov 2016 According to a Cortice Biosciences media release, data from another Phase I/II study (see profile 236577) will be utilized to design this trial with guidance provided by FDA.
- 08 Jun 2016 New trial record